PTHS Pelthos Therapeutics Inc.
Biological Products, (No Diagnostic Substances) · NYSE · SEC CIK 1919246 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY—
TTM net income YoY-231.0%
TTM EPS YoY-32.3%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—
Margins
Gross margin83.2%
Operating margin-101.6%
Net margin-152.2%
FCF margin-63.5%
EBITDA margin-98.9%
Returns
ROE-299.8%
ROA-61.2%
ROIC (approx.)-408.1%
Asset turnover0.40x
Leverage & solvency
Liabilities / assets104.8%
Debt / equity—
Current ratio1.78x
Interest coverage-6.26x
Cash quality & payout
Operating cash flow / net income0.41x
Accruals ratio-35.9%
Payout ratio—
Capex / revenue0.7%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 | FY20232023-12-31 | FY20222022-12-31 |
|---|---|---|---|---|
| Income statement | ||||
| Revenue | $16.80M | $0 | — | — |
| Cost of revenue | $3.99M | $0 | — | — |
| Gross profit | $12.81M | $0 | — | — |
| R&D expense | $1.23M | $1.18M | $2.58M | $391,730 |
| SG&A expense | $42.45M | $6.39M | $2.74M | $1.10M |
| Operating income | -$32.43M | -$7.57M | -$6.86M | -$2.32M |
| Interest expense | $3.01M | $786,000 | $309,094 | $135,630 |
| Pretax income | -$50.71M | -$7.96M | -$7.38M | -$2.46M |
| Income tax | -$7.39M | $0 | — | — |
| Net income | -$43.32M | -$7.96M | -$7.38M | -$2.46M |
| EBITDA | -$31.70M | -$7.57M | — | — |
| EPS (basic) | -23.04 | -14.27 | -5.78 | 5.65 |
| EPS (diluted) | -23.04 | -14.27 | -5.78 | — |
| Weighted avg. shares (diluted) | 1.88M | 557,447 | 1.28M | — |
| Balance sheet | ||||
| Cash & equivalents | $17.97M | $513,000 | $96,000 | $55,074 |
| Receivables | $8.86M | $0 | — | — |
| Inventory | $23.57M | $0 | — | — |
| Current assets | $53.41M | $1.37M | $96,391 | $55,074 |
| PP&E, net | $9.59M | $0 | — | — |
| Goodwill | $24.68M | $0 | — | — |
| Intangibles | $39.47M | $0 | — | — |
| Total assets | $130.40M | $1.37M | $96,391 | $55,074 |
| Current liabilities | $25.99M | $4.08M | $6.54M | $3.76M |
| Total liabilities | $91.52M | $4.08M | $6.54M | $3.76M |
| Shareholders' equity | $38.88M | -$2.71M | -$6.45M | -$3.71M |
| Shares outstanding | 3.23M | 610,389 | 3.91M | 1.11M |
| Cash flow statement | ||||
| Operating cash flow | -$22.59M | -$5.79M | -$981,031 | -$1.57M |
| Capital expenditure | $99,000 | $0 | — | — |
| Free cash flow | -$22.69M | -$5.79M | — | — |
| Investing cash flow | -$5.24M | $0 | — | — |
| Financing cash flow | $45.34M | $6.21M | $1.02M | $1.62M |
| Depreciation & amortization | $729,000 | $0 | — | — |
| Stock-based compensation | $5.46M | $1.80M | $1.73M | $110,146 |
| Share buybacks | $0 | $75,000 | — | — |
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.